Locations:
Search IconSearch
October 3, 2018/Cancer

First Prostate Surgery Performed in U.S. Using Single Port SP Robot

Surgeons completed radical prostatectomy using new-generation robot

SP-Port-Robot-1-650×450

Cleveland Clinic is the first hospital in the country to successfully perform surgeries using the Single Port SP Robot, which inserts all surgical instruments through one small abdominal incision, improving surgical outcomes and allowing quicker patient recovery.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

New generation robot used in 3 surgeries

On Sept. 28, Cleveland Clinic surgeons used the SP Robot to perform three surgeries — two surgeries to remove cancerous prostates and one surgery to remove an enlarged prostate blocking the urinary system through the bladder.

Jihad Kaouk, MD, Director of the Center for Robotic and Image Guided Surgery in the Glickman Urologic and Kidney Institute, was the first to perform and publish on robotic single-port surgery in 2008 using standard robotic systems and coining the phrase R-LESS (robotic laparoendoscopic single site surgery).

After completing and publishing the first ever clinical use for the SP robot in Europe, Dr. Kaouk and his team also performed last week’s radical prostatectomies and transvesical simple prostatectomy at Cleveland Clinic. The new purpose-built robotic SP system will allow the single port approach to be more feasible.

Making the previously impossible possible

“We anticipate that this new generation of robots will allow for new and different routes of surgeries that haven’t previously been possible,” Dr. Kaouk says. “For example, we can now go through a patient’s perineum instead of their belly to perform prostate surgery and avoid touching the bowel, or work through the retroperitoneal space to perform kidney surgery without entering the abdomen, allowing for quicker recovery time.”

Currently, the SP Robot is only FDA-approved for urologic surgeries, with plans to expand to ENT and colorectal surgeries in the near future.

“We are proud to offer this surgical approach and be on the forefront of surgical innovation,” adds Mark A. Taylor, MD, Chairman of Surgical Operations at Cleveland Clinic.

Advertisement

Dr. Kaouk worked with the Intuitive Inc. team of engineers to test and improve the new robotic system. Dr. Kaouk is a paid consultant, speaker or member of the advisory committee for Endocare, Inc. and Intuitive Surgical, Inc.

Advertisement

Related Articles

Woman wearing pink scarf
January 17, 2025/Cancer/News & Insight
Exceptional Responders to Metastatic Breast Cancer Treatment Characterized

Findings may guide future research and personalized treatments

Tumor-Infiltrating Lymphocytes (TIL) therapy
January 6, 2025/Cancer/News & Insight
Tumor-Infiltrating Lymphocytes Therapy Now Available for Treating Unresectable or Metastatic Melanoma

Cleveland Clinic Cancer Institute among select group of centers to administer highly personalized treatment

Woman with breast cancer
January 2, 2025/Cancer/News & Insight
Real-World Insights of KEYNOTE-522 Regimen Adoption for Treating Triple-Negative Breast Cancer

Real-world results reporting aims to make treatments safer and more effective

DNA strand
December 31, 2024/Cancer/News & Insight
New Data Further Support Breast Cancer Polygenic Risk Score

Ongoing clinical validation in diverse populations refine breast cancer risk substratification

Dr. Dermawan
December 24, 2024/Cancer/News & Insight
New Genomic Models for Leiomyosarcoma Treatment (Podcast)

Soft tissue pathologist discusses research into incorporating genomic data to improve risk stratification

Dr. Shahzad Raza
December 18, 2024/Cancer/News & Insight
Researchers Explore Prognostic Value of Transcriptomic Data in Multiple Myeloma

Prediction and bioinformatic data could prove valuable for therapeutic interventions targeting this malignancy

3D rendering of bispecific antibodies
December 17, 2024/Cancer/Blood Cancers
Efficacy and Safety Outcomes of Bispecific Antibodies

Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma

Ad